✦ LIBER ✦

American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study

✍ Scribed by Kim, E.; Cameron, M.; Lovera, J.; Schaben, L.; Bourdette, D.; Whitham, R.

Book ID: 125489248
Publisher: SAGE Publications
Year: 2011
Tongue: English
Weight: 295 KB
Volume: 17
Category: Article
ISSN: 1352-4585
DOI: 10.1177/1352458511412062

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ginseng in the treatment of fatigue in m

Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study

✍ Etemadifar, Masoud; Sayahi, Farnaz; Abtahi, Seyed-Hossein; Shemshaki, Hamidreza; 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 188 KB

Combination therapy with hydrocortisone

Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study

✍ Daniel Blockmans; Philippe Persoons; Boudewijn Van Houdenhove; Marina Lejeune; H 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 98 KB

Poster 218: A Randomized, Double-blind,

Poster 218: A Randomized, Double-blind, Placebo-controlled Crossover Study Using a Low-Frequency Magnetic Field in the Treatment of Fatigue in Multiple Sclerosis

✍ Giampaolo Brichetto; Mario Alberto Battaglia; Giovanna Konrad; Maria Laura Lopes 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 58 KB

Imatinib in active diffuse cutaneous sys

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center

✍ Janet Pope; Donna McBain; Lisa Petrlich; Sharon Watson; Louise Vanderhoek; Faye 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 2 views

## Abstract ## Objective To better understand the feasibility of using imatinib, a tyrosine kinase inhibitor, to treat active diffuse cutaneous systemic sclerosis (dcSSc). ## Methods We performed a 6‐month, randomized, double‐blind, placebo‐controlled, proof‐of‐concept pilot study of imatinib in